Navigation Links
Long-term HIV treatment may reduce risk for atherosclerosis
Date:8/4/2008

PITTSBURGH, Aug. 4 Antiretroviral drugs for HIV do not increase the risk for coronary atherosclerosis, a central risk factor for heart disease, according to a study led by the University of Pittsburgh Graduate School of Public Health to be published in the Aug. 8 issue of the journal AIDS and available online today. The results further suggest that antiretroviral therapy may offer men with HIV some protection against atherosclerosis hardening of the arteries, caused in part by high levels of cholesterol, smoking and other lifestyle factors.

The study, part of the Multicenter AIDS Cohort Study (MACS) initiated in 1983, measured levels of coronary artery calcification (CAC) in nearly 950 HIV-positive and HIV-negative men by CT scanning completed between 2004 and 2006. Controlling for traditional atherosclerosis risk factors such as age, family history, smoking and blood pressure, the study team found that CAC scores were almost 60 percent lower in HIV-positive men who received highly active antiretroviral therapy (HAART) for more than eight years compared to HIV-negative men.

HAART, a course of treatment that involves the combination of three or more antiretrovirals, has been associated with an increase in cholesterol and other factors associated with atherosclerosis, leading some to question whether long-term use increases the risk of heart attack.

"When we first prescribed highly active antiretroviral therapy for HIV in 1995, we were concerned about how these drugs changed lipid levels in patients and whether they would increase atherosclerosis and ultimately lead to serious heart disease," said Lawrence Kingsley, Ph.D., study lead author and associate professor, Departments of Infectious Diseases and Microbiology and Epidemiology, University of Pittsburgh Graduate School of Public Health. "While some studies have found an association between these antiretroviral treatments and increased risk of cardiovascular disease, we believe our findings should reassure clinicians that using antiretroviral therapy over time does not appear to put patients at greater risk for coronary atherosclerosis and may, in fact, be more beneficial than we had initially thought."

The study also found that for both HIV-positive and HIV-negative men, older age was most strongly associated with the presence of coronary atherosclerosis. Smoking, lipid abnormalities and family history also played a role.

"This was not surprising since these are the major risk factors for atherosclerosis in the general population," said Dr. Kingsley. "The purpose of our study, however, was to investigate whether long-term HAART usage was a major risk factor."

"These results could be due, in part, to lower lipid values of HIV infected men prior to beginning antiretroviral therapy and high use of lipid-lowering drugs. The key is that controlling risk factors for atherosclerosis should be a priority," added Lewis Kuller, M.D., Dr.P.H, study co-author and professor of epidemiology, University of Pittsburgh Graduate School of Public Health.

Dr. Kingsley concluded, "What remains to be determined is whether use of the newest antiretroviral therapies confers an even better outcome and whether lipid-lowering therapies will further improve cardiovascular risk in the HIV-infected population. Our future research will address these questions."


'/>"/>

Contact: Michele D. Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Laser Resurfacing Produces Long-Term Results
2. Ecumen Provides Presidential Candidates 10 Top Reasons to Discuss Long-Term Care Reform
3. Hearings Set for Monday as Part of Two-Year Democratic Process to Unite the Strength of California Long-Term Care Workers to Improve Their Lives and Better Serve Their Clients
4. Online NHS Health Guides for Long-Term Conditions Released on NHS Choices
5. AmeriCares Meets Long-Term Health Needs of Disaster Victims in China and Myanmar
6. Long-term care fraught with uncertainties for elderly baby boomers
7. Moms Unhealthy Diet May Have Long-Term Impact on Baby
8. Hill-Rom Announces Agreement With Tri-anim to Enhance Distribution Channels for The Vest(R) System in U.S. Hospitals & Long-Term Care Facilities
9. Governor Rendell Announces Record Response to Pennsylvanias Own Your Future Long-Term Care Planning Effort
10. Patients own infection-fighting T cells put late-stage melanoma into long-term remission
11. Long-term safety data on Lialda published in leading GI journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... ... July 23, 2017 , ... A 20-year-long study ... Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports growing ... disease offers very few benefits. , In the cases involved with this study, ...
(Date:7/23/2017)... ... July 23, 2017 , ... Technology ... safety and patient-provider relationships. New tools are helping patients become more actively involved ... Annual Health Care’s Most Wired® survey, released today by the American Hospital Association’s ...
(Date:7/23/2017)... ... July 23, 2017 , ... Viora Ltd., a ... US Patent No. 9,038,640 by the United States Patent and Trademark Office. The ... combination of Switching, Vacuum, and Cooling mechanisms to further increase the efficacy and ...
(Date:7/21/2017)... , ... July 21, 2017 , ... "As a doctor ... lot of pleural catheters available on the market," said an inventor from Center Valley, ... and safety for the patient." , He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT ...
(Date:7/21/2017)... ... July 21, 2017 , ... Roderick Crabbe Insurance, ... to families and business owners in northern Florida, is joining the First Coast ... to area adults with developmental challenges. , The First Coast YMCA offers assistance ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... 30, 2017 In vitro diagnostics market firm ... May, at least ten diagnostic companies have successfully completed ... offerings and a loan facility.  The size of these ... million.  Kalorama Information provides a monthly IVD Market ... Knowledge Center. ...
(Date:6/30/2017)... POINT, N.C. , June 29, 2017  Axium Pharmaceuticals Inc. ... for developing improved novel formulations and alternative dosage forms of ... ... delivery is based on our waterless self-nano emulsifying formula, which ... contact with saliva. We believe the spray will provide fast ...
Breaking Medicine Technology: